Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Strategy: Back to School Issue: Paying the piper

22nd BioCentury Back to School Issue: Time to try new pricing schemes

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug in the U.S. that could be given to millions of people has sparked the strongest backlash against drug pricing the industry has yet faced - in the last major market where the government has not adopted any form of drug price controls, according to the U.S. Department of Commerce.

Last year, in "Facing Reality," Back to School argued biopharma companies can no longer assume the market will support premium pricing, even for drugs that deliver meaningful and measurable improvements over the standard of care.

Full Article

Today's Biotech & Pharma News

Profiles Targeted Therapies

Subscribe Now
Free Trial